Stocks · News reference
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $457 to $469.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Humana affirms its guidance of at least $9.00 in adjusted earnings per common share ("Adjusted EPS"), for the year ending December 31, 2026 ("FY 2026"). This guidance is consistent with the guidance
CVS Health demonstrates attractive valuation and improving business performance, with Aetna's margin recovery gaining momentum and pharmacy segment showing strong prescription volume growth. However, 340B program pressures and expected Caremark membership declines pose near-term challenges. The stock trades at a discount to peers and has outperformed its industry, though technical indicators suggest weaker momentum.
Dr. Aaron L. Schwartz, an assistant professor at the University of Pennsylvania, has been awarded the 2026 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award for his groundbreaking work on low-value care metrics and prior authorization research. His claims-based measures have been adopted by CMS for accountable care programs, and his research has influenced policy decisions at major healthcare organizations and government agencies.